Table 1.
Subject | Measurement period | Average study values | References | |
---|---|---|---|---|
QT/TQ 50 | QT/TQ 98 | |||
Healthy humans | 10 s at supine resting baseline | 0.73–0.76 | 1.14 | Fossa et al. (2014), Gross, (1952) |
2‐hr supine resting baseline | 0.63 | 1.11 | Fossa and Zhou (2010) | |
2 hr at sleep | 0.65–0.70 | 1.11–1.23 | Fossa et al. (2007), Fossa and Zhou (2010) | |
24‐hr baselines | 0.70–0.85 | 1.09–1.52 | Fossa and Zhou (2010), Fossa et al. (2007, 2014)a | |
Baseline:10‐min exercise (walking) | 0.94:1.33 | NA | Yu et al. (1950) | |
Bike exercise (maximum burst) | 2.13 | 3.25 | Fossa and Zhou (2010) | |
Supine to standing | 1.09 | 1.80 | Fossa and Zhou (2010) | |
Phenylephrine bolus challenge during supine rest | 0.63 | 0.92 | Fossa and Zhou (2010) | |
Isoproterenol bolus during rest | 1.79 | 2.63 | Fossa and Zhou (2010) | |
Rheumatic carditis | 10‐s baseline | 1.46 | NA | Taran and Szilagyi (1947) |
Hypertension | Baseline:10‐min walk | 1.16:1.67 | NA | Taran and Szilagyi (1947) |
Congenital heart disease | Baseline:10‐min walk | 1.44:1.72 | NA | Taran and Szilagyi (1947) |
Pulmonary disease | Baseline:10‐min walk | 1.08:1.34 | NA | Taran and Szilagyi (1947) |
Monkey | 24‐hr ambulatory baseline | 1.01 | 1.85 | b |
Canine | 24‐hr ambulatory baseline | 0.41–0.69 | 1.20–1.60 | b |
Regulatory TQT studies submitted to FDA.
Regulatory toxicology studies submitted to FDA.